Sex hormones and the risk of heart failure.

Diagrammatic illustration of trends of incident heart failure diagnosis and diagnostic testing in the US from 2016 to 2019 stratified by inpatient and outpatient setting.

Phenogroup composition, overlap and outcomes among 643 consecutively evaluated patients with HFpEF undergoing invasive hemodynamic exercise testing. Hemodynamic and oxygen transport characteristics varied by type of and number of phenogroups present among patients (not shown).

Dilated cardiomyopathy with arrhythmic phenotype. AR, arrhythmogenic; CI, confidence interval; CIF, cumulative incidence function; ECG, electrocardiogram; FLNC, filamin C; LMNA, lamin; MVA, major ventricular arrhythmia; NSVT, non-sustained ventricular tachycardia; RBM20, RNA binding motif 20; RMTL, restricted mean time lost; SCD, sudden cardiac death.

Seventeen patients hospitalized for suspected hot-phase cardiomyopathy underwent both endomyocardial biopsy (EMB) and genetic testing: histological detection of apoptosis at EMB was frequent (77% of cases) and all patients that tested positive for pathogenic/likely pathogenic variants showed apoptosis at EMB. In patients with apoptosis at EMB, left ventricular ejection fraction was lower at first clinical presentation and improved during follow-up with anti-neurohormonal therapy.

Myocardial perfusion in cardiac amyloidosis. Images on the left panel show an example of coronary angiography, first-pass perfusion maps and stress and rest myocardial perfusion maps of a patient with cardiac amyloidosis. The coronary angiogram is unobstructed and visual analysis of first-pass perfusion shows a global reduction in myocardial blood flow. Stress myocardial perfusion maps show extensive global ischaemia. Images on the top and middle right panel are endomyocardial biopsy samples showing extensive small vessel amyloid deposition (top) and myocyte atrophy and cytoplasmic vacuolization (middle). The bottom right panel shows intramural vessels with amyloid deposits from an explanted whole heart.

Summary of study findings. HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide.

Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial. CV, cardiovascular; HF, heart failure.

Three-year outcomes of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster RCT in patients hospitalized for HF. Hospitals were randomized to a group of transitional care services versus usual care. Clinical event rates were high and the treatment effect on the primary composite outcome of all-cause death, readmission, or ED visit was neutral at 3 years, likely due to similar uptake of guideline-directed medical therapy (GDMT) in both groups. ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BB, beta-blocker; ED, emergency department; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist; RCT, randomized controlled trial; RR, relative risk.

Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction.

Study design and intended outcomes of the HF-REVERT study with CDR132L, a synthetic antisense oligonucleotide inhibitor selectively targeting microRNA-132, in patients with reduced left ventricular ejection fraction (LVEF) after myocardial infarction (MI). AMI, acute myocardial infarction; CV, cardiovascular; ECG, electrocardiogram; ECHO, echocardiography; HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LVESVI, left ventricular end-systolic volume index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PROM, patient-reported outcome measure; RCT, randomized clinical trial.

Impact of the Aria pulmonary endovascular device on hemodynamics. Hemodynamics and reservoir pressures are depicted in blue during device activation and in red when the device is deactivated. Panel A demonstrates the effect of temporary device activation on pulmonary arterial (PA) and left ventricular (LV) pressures in a patient with pulmonary hypertension associated with left heart disease (PH-LHD). Panel B shows the effect of the Aria pulmonary endovascular device on pulmonary arterial compliance (CPA) and right ventricular-to-pulmonary vascular coupling assessed by the ratio of right ventricular end-systolic elastance to effective arterial elastance (Ees/Ea) in patients with PH-LHD, PH associated with chronic lung disease (PH-CLD) and pulmonary arterial hypertension (PAH, panel C).